Bokf Na Sells 1,726 Shares of Solventum Co. (NYSE:SOLV)

Bokf Na decreased its stake in shares of Solventum Co. (NYSE:SOLV) by 32.3% during the fourth quarter, Holdings Channel reports. The firm owned 3,614 shares of the company’s stock after selling 1,726 shares during the quarter. Bokf Na’s holdings in Solventum were worth $242,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SOLV. New York Life Investment Management LLC boosted its stake in shares of Solventum by 0.7% in the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after buying an additional 136 shares during the last quarter. Blue Trust Inc. increased its holdings in Solventum by 2.1% during the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after buying an additional 161 shares during the last quarter. Avantax Advisory Services Inc. raised its position in Solventum by 2.2% in the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after acquiring an additional 192 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Solventum by 48.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock worth $45,000 after acquiring an additional 223 shares during the last quarter. Finally, Savant Capital LLC grew its position in shares of Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock valued at $259,000 after acquiring an additional 233 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. The Goldman Sachs Group lifted their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. Mizuho boosted their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, Bank of America raised their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and an average target price of $79.00.

Solventum Stock Performance

NYSE:SOLV opened at $70.22 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a market cap of $12.15 billion and a price-to-earnings ratio of 25.53. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The stock’s 50 day simple moving average is $70.17 and its two-hundred day simple moving average is $71.27.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.02 billion. Solventum’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.08 EPS. As a group, equities analysts anticipate that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.